Neurofilament Light Chain as a Biomarker in Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Due to the unpredictable course and heterogenous treatment response in multiple sclerosis (MS), there is a clear need for biomarkers that reflect disease activity in the clinical follow-up of these patients. Neurofilaments are neuron-specific components of the cytoskeleton that can be assayed in different body compartments. They have been explored as potential biomarkers for many years. Neurofilament light chain (NF-L) appears the most promising biomarker in MS patients, and there is now little doubt that NF-L should have a role in the follow-up of MS patients. Newer assays and techniques for NF-L detection available in serum samples confirms the usefulness of NF-L as a biomarker. Nevertheless, there is still a need for prospective studies, and studies to determine clinical useful cut-off values. This review evaluates the strengths and weaknesses of NF-L as a biomarker in patients with MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., Piech, T., Patel, P. P., Chang, L., Rivnak, A. J., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1641 · Cited by 2,119 · cited 1×
“com) can detect very low concentrations of single enzyme-labeled proteins (16).”
BackgroundSerum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
Disanto, G., Barro, C., Benkert, P., Naegelin, Y., Schädelin, S., Giardiello, A., Zecca, C., Blennow, K., Zetterberg, H., Leppert, D., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24954 · Cited by 1,164 · cited 8×
“healthy controls, a correlation with presence of relapses, worsening EDSS and MRI lesion activity [both T2-lesions and Gd-lesions (9)].”
BackgroundResultInfluentialAssociation of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., & Initiative, F. T. A. D. N. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6117 · Cited by 1,070
Dominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927 · cited 1×
“The important fact that serum NF-L levels correlate with CSF levels have been confirmed in several studies (9, 18, 19).”
BackgroundKuhle, J., Barro, C., Andreasson, U., Derfuss, T., Lindberg, R., Sandelius, Å., Liman, V., Norgren, N., Blennow, K., & Zetterberg, H. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-1195 · Cited by 740
Rosengren, L. E., Karlsson, J., Karlsson, J., Persson, L. I., & Wikkelsø, C. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67052013.x · Cited by 499
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
Novakova, L., Zetterberg, H., Sundström, P., Axelsson, M., Khademi, M., Gunnarsson, M., Malmeström, C., Svenningsson, A., Olsson, T., Piehl, F., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004683 · Cited by 426
Neurofilament light chain: a biomarker for genetic frontotemporal dementia
Meeter, L. H., Dopper, E. G., Jiskoot, L. C., Sanchez‐Valle, R., Graff, C., Benussi, L., Ghidoni, R., Pijnenburg, Y. A., Borroni, B., Galimberti, D., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.325 · Cited by 263
Ashton, N. J., Leuzy, A., Lim, Y. M., Troakes, C., Hortobágyi, T., Höglund, K., Aarsland, D., Lovestone, S., Schöll, M., Blennow, K., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0649-3 · Cited by 172
A comparative study of CSF neurofilament light and heavy chain protein in MS
Kuhle, J., Plattner, K., Bestwick, J. P., Lindberg, R. L., Ramagopalan, S. V., Norgren, N., Nissim, A., Malaspina, A., Leppert, D., Giovannoni, G., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513482374 · Cited by 155
Cited by
Picca, A., Guerra, F., Calvani, R., Romano, R., Coelho-Júnior, H. J., Bucci, C., & Marzetti, E. (2021) · Biomolecules · doi:10.3390/biom11101508 · Cited by 189
van der Ende, E. L., Meeter, L. H., Poos, J. M., Panman, J. L., Jiskoot, L. C., Dopper, E. G. P., Papma, J. M., de Jong, F. J., Verberk, I. M. W., Teunissen, C., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30354-0 · Cited by 181
Singer, W., Schmeichel, A. M., Shahnawaz, M., Schmelzer, J. D., Sletten, D. M., Gehrking, T. L., Gehrking, J. A., Olson, A. D., Suarez, M. D., Misra, P. P., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26089 · Cited by 102
van den Bosch, A., Fransen, N., Mason, M., Rozemuller, A. J., Teunissen, C., Smolders, J., & Huitinga, I. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001154 · Cited by 58
Das, S., Dewit, N., Jacobs, D., Pijnenburg, Y. A. L., In ‘t Veld, S. G. J. G., Coppens, S., Quaglia, M., Hirtz, C., Teunissen, C. E., & Vanmechelen, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137221 · Cited by 26
Metadata
- Authors
- Varhaug, K. N., Torkildsen, Ø., Myhr, K.-M., & Vedeler, C. A.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2019-04-05
- Volume
- 10
- Pages
- 338-338
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W2930999271
- Cited by
- 185
- References
- 10
- FWCI
- 14.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurofilament Light Chain as a Biomarker in Multiple Sclerosis. https://app.cochat.ai/papers/10.3389/fneur.2019.00338
- The paper
- Varhaug, K. N., Torkildsen, Ø., Myhr, K.-M., & Vedeler, C. A. (2019). Neurofilament Light Chain as a Biomarker in Multiple Sclerosis. Frontiers in Neurology. https://doi.org/10.3389/fneur.2019.00338
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.